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Activation of multiple signaling pathways is required to trigger the full spectrum of in vitro and in vivo
phenotypic traits associated with neoplastic transformation by oncogenic Ras. To determine which of these
pathways are important for N-ras tumorigenesis in human cancer cells and also to investigate the possibility
of cross talk among the pathways, we have utilized a human fibrosarcoma cell line (HT1080), which contains
an endogenous mutated allele of the N-ras gene, and its derivative (MCH603c8), which lacks the mutant N-ras
allele. We have stably transfected MCH603c8 and HT1080 cells with activating or dominant-negative mutant
cDNAs, respectively, of various components of the Raf, Rac, and RhoA pathways. In previous studies with these
cell lines we showed that loss of mutant Ras function results in dramatic changes in the in vitro phenotypic
traits and conversion to a weakly tumorigenic phenotype in vivo. We report here that only overexpression of
activated MEK contributed significantly to the conversion of MCH603c8 cells to an aggressive tumorigenic
phenotype. Furthermore, we have demonstrated that blocking the constitutive activation of the Raf-MEK, Rac,
or RhoA pathway alone is not sufficient to block the aggressive tumorigenic phenotype of HT1080, despite
affecting a number of in vitro-transformed phenotypic traits. We have also demonstrated the possibility of
bidirectional cross talk between the Raf-MEK-ERK pathway and the Rac-JNK or RhoA pathway. Finally, over-
expression of activated MEK in MCH603c8 cells appears to result in the activation of an as-yet-unidentified
target(s) that is critical for the aggressive tumorigenic phenotype.
The Ras superfamily of small GTPases, of which there are
more than 80 mammalian members, comprises at least nine
distinct branches. These include the Ras, Rab, RhoA, Ran,
Rheb, Rad/Gen, Rin/Rif, and Arf families (2, 3). Ras family
proteins constitute one of the three major branches of the Ras
superfamily. Members of the Ras family, namely, H-ras, K-ras,
and N-ras, have been implicated in human cancers. The asso-
ciation of mutated ras (H-, K-, and N-ras) genes with up to
30% of all human cancers suggests an important contribution
of constitutively active Ras function to the development of
human cancers (6, 28).
Early studies of the transforming activity of transfected on-
cogenes in mouse embryo fibroblasts led to the conclusion that
a single ras oncogene, alone or in cooperation with another
oncogene, e.g., myc, was sufficient to induce neoplastic trans-
formation (1, 21, 37). It is now clear that mutations of multiple
genes, including oncogenes, tumor suppressor genes, and DNA
repair genes, are necessary to convert a normal cell into a neo-
plastic cell (20, 24, 44). The functional contribution of mutant,
constitutively active Ras proteins to this progression remains
unclear. It is clear from a variety of experimental approaches
that mutant Ras has pleiotropic effects on the morphology and
growth behavior of cells. These effects include shape changes
associated with dissolution of actin microfilaments, a reduced
requirement for serum growth factors, increased motility and
invasiveness, anchorage-independent growth in vitro, and more
aggressive tumor growth in vivo (15, 31, 37, 47).
Early studies of Ras signal transduction identified the linear
transduction cascade of Ras3 Raf3MEK3 ERK3 Elk-1,
culminating in transcriptional activation of genes involved in
mitogenesis (22, 35). It has become increasingly clear, how-
ever, that this simple linear pathway represents only a minor
component of a very complex signaling circuitry (5, 10). Recent
evidence has indicated that Ras mediates its actions through
interactions with multiple effectors, both Raf dependent and
Raf independent. Additionally, there is accumulating evidence
that components of the individual linear pathways engage in
cross talk (5, 41).
This multiplicity of functionally diverse effector targets is
accompanied by a similar diversity of phenotypic consequences
of Ras activation. The activation of the Raf-dependent signal
transduction pathway results in growth promotion, following
the transcription of genes required for mitogenesis. Several
Raf-independent effectors have been shown to regulate the
actin cytoskeleton and influence cell shape and motility. Rac
induces peripheral actin accumulation and membrane ruffling,
and RhoA is involved in the induction of the assembly of stress
fibers and focal adhesions (15). Both Rac and Cdc42 assemble
focal complexes; additionally, Cdc42 induces the formation of
filopodia and Rac induces the formation of lamellipodia (2).
Phosphoinositol 3-kinase (PI3K) is a lipid kinase that phos-
phorylates phosphoinositides and also has been implicated as a
Ras effector (36). PI3K-induced activation of protein kinase
B/Akt, which activates Bad via phosphorylation, leading to
phosphorylation-induced inactivation of procaspase 9, consti-
tutes an antiapoptotic survival signal (12).
This bewildering complexity of Ras effector functions has
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made it difficult to determine those functions that are critical
for neoplastic transformation. For example, it has been re-
ported that interaction of activated Ras with Raf-1 alone is
sufficient for transformation of Rat-2 cells (4). It was also
reported that activating mutants of MEK were necessary and
sufficient for neoplastic transformation of mouse NIH 3T3
cells (25). However, it has also been reported that Ras effector
domain mutants that selectively activate Raf-independent
pathways induce neoplastic transformation of NIH 3T3 cells
(19, 47).
Most studies of the transforming effects of Ras or Ras ef-
fector proteins have employed transfection of the relevant
oncogene(s) into rodent cells. The major reason for this is that
rodent cells are readily transformed by these oncoproteins
whereas normal human cells are refractory to their transform-
ing effects (38, 44). Thus, it is possible that rodent experimen-
tal models may not accurately reflect the physiologic conse-
quences of expression of mutant Ras and Ras-related proteins
in human cells.
We have had a long-standing interest in the role of mutant
Ras function in human cancers. Our earlier studies showed
that expression of mutant Ras was not sufficient to neoplasti-
cally transform normal or immortalized human cells (7, 44).
More recently, we have shown that deletion of endogenous
mutant Ras alleles in human cancer cells does not result in loss
of tumorigenicity (31). However, the loss of mutant Ras func-
tion resulted in profound pleiotropic phenotypic alterations in
vitro, resulting in many features of reverse transformation.
Furthermore, the kinetics of tumor growth are significantly
affected; those cells lacking mutant Ras formed tumors more
slowly. We also found interesting differences in the pathways
activated by mutant Ras, depending on whether mutant N-ras
or K-ras was involved (32).
We have extended these observations in the present study in
an attempt to decipher which individual pathway(s) is critical
for the transformed and aggressive tumorigenic phenotypes.
Our model system is the HT1080 human fibrosarcoma cell line.
These are pseudodiploid cells possessing a single mutant N-ras
allele (27). We have isolated a variant, termed MCH603c8, in
which the mutant N-ras allele has been deleted (31). The
parental HT1080 cells exhibit typical features of a transformed
cell in culture, including poor adherence, anchorage-indepen-
dent growth, and disorganized actin and aggressive tumor for-
mation. The MCH603c8 variants have more normal growth
characteristics, including a flat adherent morphology, anchor-
age-dependent growth, and well-organized actin microfila-
ments. The cells are weakly tumorigenic—tumors are formed
in all animals inoculated with the cells, but they grow signifi-
cantly more slowly than HT1080 cells (31).
Examination of the Ras signal transduction pathways in
HT1080 cells showed that downstream members of all path-
ways examined, Raf dependent and Raf independent, have
high constitutive activities (32). Conversely, MCH603c8 cells
showed only low basal activity except for a lower level of
constitutive ERK activity and constitutively activated protein
kinase B/Akt and p38. The latter constitutive activities are
probably due to the fact that both HT1080 and MCH603c8
secrete platelet-derived growth factor (PDGF), which binds to
and activates its cognate receptor (R. Plattner and S. Gupta,
unpublished observation), followed by activation of PI3K.
Utilizing either dominant-negative (DN) or constitutively
active mutant cDNAs of members of the Raf, Rac, and RhoA
pathways, we have downregulated or upregulated individual
arms of the Ras signal transduction pathways in HT1080 and
MCH603c8 cells, respectively. Distinct alterations in in vitro
and in vivo phenotypic traits are seen and provide evidence for
a possible novel signaling pathway that is required for the
aggressive tumorigenic phenotype.
MATERIALS AND METHODS
Molecular constructs. The mutants used in this study are listed in Table 1. The
expression construct pCMV(hyg)Raf(22W) was derived from pZipRaf(22W),
which encodes an NH2-terminally truncated human Raf-1 that is catalytically
active (49). The construct pCGN(hyg)RafC encodes truncated Raf, which lacks
the Ras binding sequences (8) and is catalytically inactive. The construct pmc1
(hyg)MEK1DED encodes a mutated MEK cDNA in which two serine codons in
the regulatory site, namely, codons 218 and 222, have been mutated to glutamic
and aspartic acid, respectively (25). The mutant MEK also has an NH2-terminal
deletion of amino acids 31 to 52. This region acts as a nuclear export signal, and
this signal directs cytoplasmic localization or nuclear exclusion of MEK (13).
This results in a catalytically active protein that has been shown to have potent
transforming activity for mouse NIH 3T3 cells. The construct pCMV(neo)
MEK-KA(101A) encodes a mutant MEK in which the ATP binding site has
been mutated, rendering it catalytically inactive (30). pCMV(neo)Rac(17N)
encodes a mutated Rac in which codon 17 (serine) has been changed to
asparagine, rendering it catalytically inactive (18). Also, pCMV(hyg)Rac1
(115I) encodes a mutated Rac in which codon 115 (asparagine) has been
changed to isoleucine, resulting in a catalytically active protein (18). pCMV
(hyg)RhoA(63L) was derived from pZip-RhoA(63L), which encodes RhoA,
where codon 63 has been changed from glutamine to lysine, rendering it
constitutively active. pCMV(neo)RhoA(19N) encodes RhoA, where codon 19
has been changed from serine to asparagine and is catalytically inactive (18).
Cell culture and stable transfection. The HT1080 cell line contains one mutant
and one wild-type N-ras allele (27, 31). MCH603c8 contains only wild-type N-ras
(31). The cell lines were grown in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal calf serum (FCS) (Life Technologies).
The HT1080 and MCH603c8 cell lines transfected with the various mutant
cDNAs were maintained in their respective antibiotic selection media prior to
experimentation. Subconfluent (70%) 100-mm-diameter dishes of MCH603c8
cells or HT1080 cells were transfected with 5 mg of linearized DNA or vector
control DNA, using 30 ml of Lipofectin (Gibco BRL) in OPTIMEM medium
(Gibco BRL). Clones from each transfection were selected and maintained in
medium containing the relevant selective antibiotic (either 800 mg of Geneticin
[Gibco BRL]/ml or 36 U of hygromycin B [Calbiochem]/ml).
TABLE. 1. DN and constitutively active mutants used in this study
Mutant Mutation Mechanism Reference
Dominant negative
Raf C Lacks Ras binding regions; contains kinase domain and
MEK binding domain; encodes C-terminal fragment
of human Raf-1
Forms a complex with endogenous MEK and inhibits
its activation
8
MEK1(101KA) Codon 101 (lysine) mutated to alanine Phosphorylation site has been made catalytically inactive 19
Rac1(17N) Codon 17 (serine) mutated to asparagine Forms inactive complexes with Rac-specific GEFs 18
RhoA(19N) Codon 19 (serine) mutated to asparagine Forms inactive complexes with Rho-specific GEF(s) 18
Constitutively active
Raf(22W) N-terminal end of Raf-1 is truncated Forms catalytically active Raf-1 49
MEK1DED Codon 218 (serine) mutated to glutamic acid; codon 222
(serine) mutated to aspartic acid
Phosphorylation site (serine) has been mutated to make
it catalytically active
25
Rac1(115I) Codon 115 (asparagine) mutated to isoleucine Forms catalytically-active Rac-1 18
RhoA(63L) Codon 61 (glutamine) mutated to leucine Forms catalytically active RhoA 18
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Growth kinetics. To assess in vitro growth kinetics, 104 cells were seeded in
triplicate in T25 flasks containing DMEM–10% FCS. The cells were harvested
on various days and counted in a Coulter counter. The growth medium was
replenished at regular intervals.
Growth in soft agar. Cells (104 or 106) were seeded in suspension in a 0.3% top
agar overlay (in DMEM–10% FCS) above a 0.5% bottom agar layer (in DMEM–
10% FCS) in 60-mm-diameter dishes as previously described (31). The plates
were fed periodically with 1 ml of DMEM–10% FCS. Colonies (.0.1-mm di-
ameter) were counted after 3 weeks.
Actin cytoskeleton staining and morphology. Actin stress fibers were visual-
ized by staining cells with fluorescein-conjugated phalloidin (Molecular Probes).
Two days after being plated on slide chambers, the cells were fixed in 3.7%
paraformaldehyde, treated with 0.1% Triton X-100 solution, and then stained
with phalloidin (0.005 U/ml) for 20 min at room temperature and mounted in
ProLong fade-antifade (Molecular Probes).
Activated Ras, Rac, and RhoA assays. Subconfluent cells were serum starved
for 18 h and then lysed with 13 Mg21 lysis buffer (Ras and Rac activation assay
kits; Upstate Biotechnology). Each of the cell lysates (500 mg) was affinity
precipitated with 10 ml of Raf-1 Ras binding domain or PAK-1 p21 binding
domain (PBD) agarose or glutathione S-transferase–2 C21 Sepharose conjugate
(40) at 4°C overnight for the Ras, Rac-Cdc42, or RhoA activation assay, respec-
tively. The beads were collected, washed, and resuspended in 63 Laemmli
sample buffer. Western blot analysis was performed as described previously (9),
using 1 mg (each) of mouse monoclonal anti-Ras, anti-Rac, and anti-RhoA
(Santa Cruz Biotechnology) antibodies/ml. Horseradish peroxidase-conjugated
anti-mouse immunoglobulin G (Santa Cruz Biotechnology) was used as the
secondary antibody. A chemiluminescence detection system (Pierce) was used
for detection of the relevant proteins. To determine the total Ras, Rac, or RhoA
level, immunoblots were performed using N-ras (F155), Rac1 (C-14) or RhoA
(26C4) antibodies (Santa Cruz Biotechnology) that recognize total protein.
Kinase assays. MEK, ERK, and JNK kinase assays (New England Biolabs)
were performed according to the manufacturer’s protocols using subconfluent
cultures serum starved (0.25% FCS) for 18 h. For the MEK and ERK proteins,
500 mg of total cell lysate was immunoprecipitated with the relevant antibodies.
JNK was precipitated from 250 mg of total cell lysate using the c-Jun fusion
protein bead procedure (New England Biolabs). The activated MEK assay was
carried out by incubating immunoprecipitated phospho-MEK with ERK protein
and cold ATP (MEK1/2 kinase assay kit; New England Biolabs). The activated
ERK assay was carried out by incubating immunoprecipitated phospho-ERK
with Elk-1 fusion protein and cold ATP (p44/p42 ERK assay kit; New England
Biolabs). The JNK assays were carried out by incubating the JNK–c-Jun fusion
protein complex with cold ATP (JNK/SAPK assay kit; New England Biolabs). All
of the kinase reactions were performed at 30°C for 30 min in the kinase reaction
mixture of 25 mM Tris (pH 7.5), 5 mM b-glycerophosphate, 2 mM dithiothreitol,
0.1 mM sodium orthovanadate, and 10 mM MgCl2. The reactions were stopped
by addition of 63 Laemmli sample buffer, and the proteins were separated on
sodium dodecyl sulfate–8% polyacrylamide gel electrophoresis. For MEK, ERK,
and JNK assays, the relevant gel was transferred onto an Immobilon membrane
and Western blot analysis was performed. The blots were performed using
phospho-ERK (Thr202-Tyr204) monoclonal antibody for the MEK assay, phos-
pho-Elk-1 (Ser383) polyclonal antibody for the ERK assay, and phospho-c-Jun
(Ser63) polyclonal antibody for the JNK assay. The Raf-1 assay was performed
as described by Graham et al. (14). Total Raf-1 protein was immunoprecipitated
from 500 mg of total cell lysate with polyclonal Raf-1 antibody. The Raf-1 assay
was carried out in a coupled assay using MEK and mitogen-activated protein
kinase (MAPK) substrates as intermediates and g-32P-labeled ATP (33). For the
Raf-1 assay, the g-32P-labeled MAPK proteins in the gel were visualized by
autoradiography. To determine the total Raf, MEK, ERK, and JNK levels,
immunoblots were performed, using the respective antibodies that recognize
total protein.
Dual luciferase reporter assays. To measure Elk-1 activation, a dual luciferase
reporter assay kit (Promega) was used. Cells were transiently transfected using
the liposome-mediated transfection technique (Lipofectin; Gibco BRL), with 2.5
mg of the 53 Gal-luciferase reporter, and 0.25 mg of the pMMLV–Gal–Elk-1
expression construct (obtained from M. Karin and R. Triesman, respectively).
pRL-cytomegalovirus Renilla luciferase (0.02 mg) was used as the internal control
reporter vector. After transfection, the cells were serum starved by incubation in
DMEM containing 0.25% FCS and were lysed 18 h later in 13 cell lysis reagent
(Promega). Twenty microliters of cell lysate was analyzed for luciferase activity
using a Moonlight 2010 luminometer (Analytical Luminescence Laboratory).
Tumorigenicity asssays. Tumorigenicity was assessed by subcutaneous injec-
tion of 107 cells, resuspended in 0.2 ml of DMEM, into the flanks of 4- to
6-week-old nude athymic mice. Tumors were measured in three dimensions with
linear calipers at weekly intervals.
RESULTS
Biochemical characteristics of the parental and transfectant
cell lines. We have shown previously that the Raf–MEK–
ERK–Elk-1 pathway, as well as JNK, is constitutively active in
HT1080 and downregulated in MCH603c8 cells (32). We have
expanded those studies here and shown, as expected, that high
levels of constitutively activated Ras-GTP, Rac-GTP, and
RhoA-GTP are found in HT1080 cells whereas only very low
levels are seen in MCH603c8 cells (Fig. 1A, B, and C, respec-
FIG. 1. Pull-down assays of activated Ras, Rac, and RhoA. The GTP-bound forms of Ras, Rac, and RhoA were pulled down with glutathione S-transferase fusion
proteins, corresponding to the Ras binding domain of Raf-1, PBD of human PAK-1, and C21 binding domain of RhoA, respectively, conjugated to agarose beads. The
Ras-GTP, Rac-GTP, and RhoA-GTP proteins bound to the beads were identified using anti-Ras (A) anti-Rac (B), and anti-RhoA (C) antibodies, respectively, in a
Western immunoblot. Immunoblot analysis of total cell lysates identified the levels of total protein. HT, HT1080 cells; 603, MCH603c8 cells; V, vector-only control.
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tively). In order to investigate the roles that these pathways
play in the differential expression of the transformed and tu-
morigenic phenotypes in these cell types, the following studies
were designed to individually downregulate or activate these
pathways in HT1080 and MCH603c8 cells, respectively. In
addition, we sought to discover evidence for cross talk between
the Ras signaling pathways.
(i) Modulation of constitutively active Raf levels. The
HT1080-Raf DN transfectants showed decreased constitutive
activity of all members of the Raf-dependent pathway. The
levels of activity were approximately equivalent to those seen
in the MCH603c8 cells (Fig. 2A). Moreover, as shown in Fig.
2A, the Raf-1 DN transfectants showed normal levels (corre-
sponding to that in HT1080) of endogenous total Raf-1, as well
as the expressed truncated mutant RafC. There was no obvious
evidence of negative-feedback cross talk between the Raf and
Rac pathways. Both Rac (Fig. 1B) and JNK (Fig. 2A) retained
the same levels of activity that are seen in the parental HT1080
cells. Also, there was no evidence of cross talk between the Raf
and RhoA pathways (Fig. 1C). Furthermore, elevated Ras-
GTP levels were maintained in the transfectants (Fig. 1A). The
Raf DN protein fails to bind to Ras but forms a complex with
MEK and is predicted to block MEK function (8). This is,
indeed, what we observed. Unexpectedly, we also observed a
decreased constitutive activity of endogenous Raf in these
cells, as measured in this assay. A possible reason for this is
that the Raf activity assay involves binding of immunoprecipi-
tated total Raf protein to a MEK substrate and that the Raf
DN protein has a higher affinity for the MEK substrate, pos-
sibly masking endogenous active Raf-mediated phosphoryla-
tion of the MEK substrate. Although possible, this is not the
likely explanation, since the MEK substrate is in excess. An-
other possibility is that the Raf DN protein interferes with the
activation of endogenous Raf by the endogenous mutant Ras.
Further experiments are required to resolve this.
The MCH603-Rafact transfectants all exhibited the pre-
dicted increase in constitutive Raf activity, as well as activation
of the respective downstream members of the pathway: MEK
3 ERK3 Elk-1 (Fig. 2B). The level of constitutive activity of
each member was slightly above that seen in the HT1080 cells
(approximately 1.3- versus 1.0-fold, respectively). Clear evi-
dence of cross talk was seen, with an increase in constitutive
JNK activity to a level commensurate with that seen in
HT1080. The Rac and RhoA binding protein assays showed
that cross talk occurred at the level of Rac as well as RhoA.
The data in Fig. 1B and C show clear evidence of elevated
levels of Rac- and RhoA-GTP, respectively. However, there
was no elevation in Ras-GTP levels in the transfectants (Fig.
1A). Thus, the JNK activation due to cross talk seems to be
Ras independent and may be Rac dependent. This pattern
differs from that of the HT1080-Raf DN transfectants in that
the latter did not show evidence of a diminution in levels of
activated JNK, Rac-GTP, or RhoA-GTP. Thus, the constitu-
tive activity of JNK in the latter transfectants is probably due to
activation from the endogenous activated Rac.
FIG. 2. In vitro Raf, MEK, ERK, and JNK kinase assays and Elk-1 activation assays performed on HT1080 (HT)-Raf DN transfectants (A) and MCH603c8
(603)-Rafact transfectants (B). For the kinase assays, the fold level is relative to 1.0 for HT1080 control cells, and the Elk-1 luciferase reporter activities are expressed
as percents relative to 100% for HT1080. Three independent Raf DN clones and Rafact clones were analyzed. V, vector-only control. The error bars indicate standard
deviations.
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(ii) Modulation of constitutively active MEK levels. The
MEK DN protein used in these studies functions by binding
the endogenous activated Raf in HT1080 cells, thereby pre-
venting its activation of endogenous MEK. Thus, the MEK DN
protein functions as a RAF inhibitor whereas the previously
described Raf DN protein is an inhibitor of activated MEK.
The HT1080-MEK DN transfectants all showed significant
decreases in constitutive MEK, ERK, and Elk-1 activities, ap-
proximating the levels seen in MCH603c8 cultures (Fig. 3A).
No decrease in Raf activity was noted, indicating that “back
talk” from MEK did not occur. There was, however, a signif-
icant decrease in JNK activity. This result was somewhat un-
expected because Rac-GTP levels remained elevated (Fig. 1B)
and previous studies have shown that Ras activation of JNK is
dependent on the presence of activated Rac (23). The reason
why Rac-GTP levels remain high in the HT1080-MEK DN
cells is presumably because the mutant Ras constitutively ac-
tivates Rac. We also observed that decreased constitutive ac-
tivity of endogenous MEK in HT1080-MEK DN cells had only
a modest effect on the constitutive levels of RhoA-GTP (Fig.
1C). This again is likely due to the continued expression of
mutant N-ras in these cells, activating endogenous RhoA.
The MCH603c8-MEKact transfectants showed normal levels
of endogenous total MEK protein in addition to the exogenous
truncated mutant MEKact protein (Fig. 3B). The MCH603c8-
MEKact transfectants all had a significantly increased level of
constitutive MEK activity that was approximately threefold
higher than that seen in HT1080 cells (and 10-fold higher than
that in MCH603c8 cells). Modestly elevated levels of constitu-
tive ERK and Elk-1 activities were also noted—approximately
1.5- to 2.25-fold higher than that seen in HT1080 cells (Fig.
3B). Again, cross talk was observed, with activation of both
Rac and JNK (Fig. 1B and 3B). The levels of constitutive Rac
and JNK activities were approximately the same as those seen
in HT1080 cells.
The fact that HT1080-Raf DN transfectants (presumably
still containing endogenous activated Raf) do not inhibit JNK
activity whereas the HT1080-MEK DN transfectants do might
indicate that Raf rather than MEK activation is required for
JNK activation. However, in the case of the MCH603-MEKact
transfectants, where Raf is not activated and there is no mutant
N-ras, there is clear evidence of JNK activation (Fig. 3B).
Taken together, the data indicate that cross talk is possible at
the level of MEK or involving its downstream partner(s), re-
sulting in the enhancement of JNK activation.
(iii) Modulation of constitutively active Rac levels. The
HT1080-Rac DN transfectants possessed a reduced level of
constitutive JNK activity (Fig. 4A). There was also a corre-
sponding reduction in the level of constitutive Raf activity, to
a level approximating that seen in MCH603c8 cells, suggestive
of negative cross talk between Rac and Raf. Unexpectedly,
there was no corresponding reduction in the constitutive levels
of activity of MEK, ERK, or Elk-1 (Fig. 4). Thus, although
there is clear evidence for some interaction between Rac and
Raf, the fact that N-ras remains constitutively active (Fig. 1A)
leaves open the possibility that Ras may activate MEK via a
FIG. 3. In vitro Raf, MEK, ERK, and JNK kinase assays and Elk-1 activation assays performed on HT1080 (HT)-MEK DN transfectants (A) and MCH603c8
(603)-MEKact transfectants (B). Fold levels were calculated as for Fig. 2. Three independent MEK DN clones and MEKact clones were analyzed. V, vector-only control.
The error bars indicate standard deviations.
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pathway bypassing Raf. The continued significant levels of
Rac-GTP in the HT1080-Rac DN transfectants may be due to
the constitutive activation of endogenous Rac by the endoge-
nous mutant N-ras protein and the existence of multiple Rho
guanine nucleotide exchange factors (GEFs) which are not all
completely inhibited by interaction with the Rac DN protein.
Also, the endogenous mutant N-ras protein may be able to
activate endogenous Rac via a mechanism that does not in-
volve the GEFs that form unproductive interactions with the
Rac DN protein. It is known that the size of the Rho-GEF
family far exceeds that of Rho-GTPases, thus raising the pos-
sibility of redundancy of GEF function (42). The transfected
Rac DN protein presumably does not interfere with the pull-
down of the endogenous Rac-GTP, since it does not bind to
PAK PBD. The mechanism by which the Rac DN protein
interferes with JNK activation, even though there is evidence
of continued levels of endogenous active Rac-GTP, is not
known but may well occur in a PAK-independent fashion. A
possible explanation is that, in the presence of Rac DN pro-
tein, one or more GEFs that are capable of activating endog-
enous Rac may do so in a fashion that precludes activation of
downstream JNK. One such candidate is the GEF Tiam-1,
which is a potent Rac GEF that stimulates PAK-1 but is a poor
inducer of JNK activation (51). There was no evidence of
negative cross talk between the Rac and RhoA pathways (Fig.
1C). This, again, could be due to the persisting levels of en-
dogenous Rac-GTP in these transfectants
The MCH603-Racact transfectants, as expected, showed in-
creased Rac (Fig. 1B) and JNK (Fig. 4B) activities but no
increased Ras activity (Fig. 1A). Additionally, there was clear
evidence of cross talk with the Raf-dependent pathway. In this
case, all members showed increased levels of activity, approx-
imating those seen in HT1080 cells. Thus, activated Rac effec-
tively cross activates Raf, possibly via PAK-1 (2, 33), in these
cells. In contrast, although HT1080-Rac DN transfectants had
decreased levels of activated Raf, this inhibition did not extend
to the downstream members, MEK, ERK, and Elk-1 (Fig. 4).
Furthermore, commensurate with the increase in Rac activity,
there was a corresponding increase in RhoA (Fig. 1C).
(iv) Modulation of constitutively active RhoA levels. The
HT1080-RhoA DN transfectants resulted in a reduced level of
RhoA-GTP (Fig. 1C). Other than that, there was no corre-
sponding reduction in the constitutive levels of activity of Ras,
Rac, JNK, Raf, MEK, ERK, or Elk-1 (data not shown), sug-
gesting a lack of negative-feedback cross talk. The MCH603-
RhoAact transfectants, as expected, showed increased RhoA-
GTP levels (Fig. 1C), but no increased Ras, JNK, Raf, MEK,
ERK, or Elk-1 levels were observed (data not shown). How-
ever, there was clear evidence of a corresponding increase of
Rac-GTP levels in the MCH603-RhoAact transfectants (Fig.
1B), indicating cross talk between RhoA and Rac.
Cell shape and cytoskeletal architecture alterations. We
have previously reported (31) that HT1080 cells (mutant N-
ras) are rounded, with a lack of actin stress fibers in the cyto-
plasm and accumulation at the cell margins. The cells also
show features of membrane ruffling. Conversely, MCH603c8
cells (wild-type N-ras only) are flat with well-organized cyto-
plasmic actin stress fibers and little evidence of membrane
FIG. 4. In vitro Raf, MEK, ERK, and JNK kinase assays and Elk-1 activation assays performed on HT1080(HT)-Rac DN transfectants (A) and MCH603c8
(603)-Racact transfectants (B). Fold levels were calculated as for Fig. 2. Three independent Rac DN clones and Racact clones were analyzed. V, vector-only control.
The error bars indicate standard deviations.
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ruffling. Examples of these phenotypes are shown in Fig. 5A
and B.
It has been reported that transient expression of activated
Ras, Rac, or RhoA in cells results in formation of actin stress
fibers (15, 17, 39). However, chronic stimulation of these path-
ways, as seen in Ras-transformed cells, results in inhibition of
stress fiber formation (2). Thus, chronic Ras-mediated activa-
tion of Raf-dependent and/or Raf-independent pathways may
promote the loss of stress fibers and induce cell rounding. It
may then be expected that inhibition of Ras-mediated chronic
stimulation of one or more of these pathways may restore
organized actin stress fibers. Consistent with this possibility, we
found that expression of the MEK DN protein restored actin
stress fibers in HT1080 cells (Fig. 5D). However, although DN
Raf blocked MEK and ERK activation in HT1080 cells, it did
not restore stress fibers (Fig. 5C). Furthermore, activated Raf
expression in MCH603c8 cells did not cause the same pro-
found loss of stress fibers in MCH603c8 cells as was seen with
activated MEK (Fig. 5G and H, respectively). Thus, Ras acti-
vation of the MEK-ERK pathway in HT1080 cells may be
necessary, but not sufficient, to promote Ras-mediated loss of
stress fibers.
Since expression of constitutively active Raf and MEK in
MCH603c8 cells also caused activation of the Rac-JNK path-
way, this pathway may also contribute to Ras-induced stress
fiber loss. We did find that expression of the Rac DN protein
in HT1080 cells caused a partial restoration of stress fibers and
a flatter shape (Fig. 5E). However, introduction of activated
Rac alone into MCH603c8 cells did not cause any loss of stress
fibers (Fig. 5I). Thus, Ras activation of the Rac-JNK pathway
may also contribute to stress fiber loss, but its activation alone
is also not sufficient. Finally, expression of DN RhoA did not
cause a restoration of stress fibers in HT1080 transfectants, nor
did expression of activated RhoA cause a loss of stress fibers in
MCH603c8 cells (Fig. 5F and J, respectively), though there was
evidence of an enhancement of adhesion plaques (Fig. 5J).
Thus, in these fibrosarcoma cells, Ras-induced loss of stress
fibers seems to be mediated primarily, but not exclusively,
through chronic MEK and JNK activation. It is formally pos-
sible that some of the effects we observed may be due to
autocrine effects, wherein secreted factors may influence this
phenotype. However, conditioned medium from HT1080 cells
did not influence the organization of actin stress fibers in
MCH603c8 cells or its transfectants and, correspondingly, con-
ditioned medium from MCH603c8 cells had no effect on the
organization of stress fibers in HT1080 or its transfectants
(data not shown).
In vitro growth kinetics. Growth curves of HT1080,
MCH603c8, and their various transfectants are shown in Fig. 6.
The HT1080-Raf DN, Rac DN, and RhoA DN clones had
growth rates intermediate between those of HT1080 and
MCH603c8 cells (Fig. 6A). The MEK DN cells are the slowest
growing of the transfectants, although they grow more rapidly
than MCH603c8 cells (Fig. 6A). All of the constitutively
active MCH603c8 transfectants, Rafact, MEKact, Racact, and
FIG. 5. Actin stress fiber organization in parental HT1080 (HT) and MCH603c8 (603) cells and their respective DN and constitutively active mutant transfectants.
The cells were stained with fluorescein-conjugated phalloidin. The arrows indicate the enhancement of adhesion plaques. Magnification, 3200
FIG. 6. In vitro growth kinetics of parental HT1080 (HT) and MCH603c8
(603) cells and their respective DN and constitutively active mutant transfectants.
The error bars indicate standard deviation.
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RhoAact, had growth rates identical to that of the parental
MCH603c8 cells (Fig. 6B). Similar growth curves were carried
out under low-serum conditions (0.25% FCS). None of the
parental or transfectant cell lines grew appreciably under these
conditions (data not shown).
Growth in soft agar. We showed previously that HT1080
cells formed colonies in soft agar at low (104 cells) and high
(106 cells) densities of plating in soft agar in 60-mm-diameter
petri dishes. Conversely, MCH603c8 did not grow under any of
these conditions (31). In the case of the HT1080 DN transfec-
tants, the MEK DN cells failed to form colonies when plated at
104 per 60-mm-diameter dish (Fig. 7A). The Raf DN and
RhoA DN cells formed colonies, but to a lesser degree than
the HT1080 parental cells. Rac DN transfectants formed col-
onies as well as HT1080 did. When plated at the higher density
of 106 cells per dish, all of the transfectants formed colonies in
soft agar at an efficiency comparable to that seen with the
HT1080 cells (Fig. 7B). None of the MCH603c8 transfectants
expressing activated Raf, MEK, Rac, or RhoA formed colonies
in soft agar when plated at 104 cells per dish (Fig. 7C). How-
ever, MEKact transfectants did form colonies when plated at
the higher density of 106 cells per dish, whereas none of the
other MCH603c8 transfectants did so (Fig. 7D). Thus, the
ability of MCH603-MEKact cells to form colonies in soft agar
at the higher density is consistent with the aggressive tumori-
genic phenotype (see below). As was noted with the actin stress
fiber experiments, there was no effect of conditioned medium
from HT1080 or MCH603c8 on the anchorage-independent
growth of any of the transfectants (data not shown).
In vivo tumor formation. As previously reported (31) and
illustrated in Fig. 8, HT1080 and MCH603c8 are both tumor-
igenic in athymic nude mice. However, the kinetics of tumor
expansion differ significantly. HT1080 is aggressively tumori-
genic, with large tumors ($600 mm3) forming within 20 days.
The MCH603c8 tumors follow a more indolent course, with
tumor sizes of $400 mm3 within 70 days. None of the HT1080
DN transfectants had altered tumor kinetics, and they retained
their aggressive tumorigenic phenotype (Fig. 8A). Similarly,
none of the MCH603c8 activating transfectants showed altered
tumor kinetics, with the singular exception of the MCH603c8-
MEKact cells. These cells not only converted to an aggressive
tumorigenic phenotype but were significantly more aggressive
than the HT1080 cells (Fig. 8B). Representative tumor recon-
stitutes were established in cell culture and reimplanted into
nude mice. They retained their original phenotype of weak or
aggressive tumor formation (data not shown).
DISCUSSION
N-, H-, and K-ras genes are commonly mutated in human
cancers. The mutant Ras proteins constitutively orchestrate
signal transduction, involving multiple branched pathways and
culminating in metabolic signals that influence the malignant
phenotype of cancer cells. Despite intensive scrutiny, it is still
unclear which elements of these multiple signaling pathways
are critical for neoplastic behavior. Experimental models have
often consisted of overexpression of transduced mutant ras
genes in rodent cells, a paradigm that does not necessarily
emulate physiological conditions of endogenous mutant Ras
expression and activation in human cancer cells. In this study
we have attempted to manipulate the activation of endogenous
components of the Raf, Rac, and RhoA pathways in the
HT1080 human fibrosarcoma cell line, which contains an en-
dogenous mutant allele of N-ras, and its derivative MCH603c8
cell line, which lacks the mutant allele.
Downregulation of Ras signaling pathways in HT1080 cells.
DN mutants of Raf, MEK, and Rac all showed evidence of
downregulation of activity of downstream members of the lin-
ear pathway involved (Fig. 2 to 4 and 9). No evidence was
found for downregulation of upstream members of the respec-
tive linear pathways. Thus, a unidirectional flow of activation is
implied from these results. This is confirmed with the activa-
tion studies in MCH603c8 (see below).
There were two unexpected observations in the experiments
FIG. 7. Anchorage-independent assays. A total of 104 (A and C) and 106 (B and D) cells were plated per 60-mm-diameter petri dish in soft agar. Colonies (.0.1-mm
diameter) were counted after incubation for 3 weeks at 37°C, with periodic refeeding with fresh growth medium. HT, HT1080 cells; 603, MCH603c8 cells; V, vector-only
control. The error bars indicate standard deviations.
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with the DN proteins. We found that endogenous activated
Raf levels decreased in the HT1080-Raf DN transfectants.
Since the Raf DN protein functions to inhibit MEK activation
(8) and our Raf assay is a coupled reaction that involves im-
munoprecitation of total Raf, one would expect to measure the
activity of the endogenous Raf activated by the endogenous
mutant N-ras protein. We do not know why this level of activity
is not seen. Possibly, the Raf DN protein interferes with en-
dogenous activation of the MEK substrate. This is unlikely,
given that the MEK substrate is in excess. Another possibility
is that the kinetics of interaction of the Raf kinase inhibitor
with Raf-1 may be altered, providing a greater suppression of
activation of the Raf-MEK-ERK pathway. It is known that the
Raf kinase inhibitor coimmunoprecipitated with Raf-1, using
Raf-1 antibodies (50).
Since Rac DN protein functions by unproductively interact-
ing with members of the family of Rho-GEF proteins, it might
be expected that levels of endogenous Rac-GTP would be
decreased in the HT1080-Rac DN transfectants. This was not
the case (Fig. 1B). Given that there are multiple GEFs capable
of interacting with Rac protein, it is possible that Rac DN
protein did not sequester all of the GEFs capable of interacting
with the endogenous Rac protein. Further experimentation is
necessary to resolve these unexpected findings.
Each of the DN mutants caused downregulation of the ac-
tivities of its downstream members to levels approximating that
seen in MCH603c8 cells, which lack the mutant N-ras allele.
Thus, each of the DN mutants is potent in the sense of reduc-
ing the activities of downstream members in the respective
linear pathway. However, the expression of the DN mutants
did not have a significant effect on the levels of expression of
total protein of each member of the respective pathway (data
not shown).
Activation of Ras signaling pathways in MCH603c8 cells.
Expression of each of the activating mutants of Raf, MEK, and
Rac resulted in potent activation (Fig. 5 to 7) of the relevant
protein and respective downstream members. Activation of
upstream members was not observed. Thus, back talk within a
linear pathway was never observed whether the originating
signal was inhibitory (HT1080-DNs) or activating (MCH603c8-
Acts). Most of the constitutively active mutants examined con-
tained levels of activated protein that approximated that seen
in HT1080 cells. This was also true of the activated levels of
endogenous downstream members within the respective linear
pathway. Since the derivative cell lines are stable transfectants,
it is not known whether the absence of clones expressing sig-
nificantly higher levels of activated protein indicates that such
elevated levels are toxic to the cells. Such a phenomenon has
been noted with overexpression of oncogenic Ras and Raf
mutants, which may result in apoptosis or differentiation rather
than neoplastic transformation (26, 43). A significant exception
to this observation in our studies was the MCH603c8-MEKact
clones. Each clone had an approximately 3-fold-higher level of
activated-MEK expression than that seen in HT1080 cells (and
a 10-fold higher level than in MCH603c8 cells). Levels of
activated ERK and Elk-1 were also higher (1.5- to 2-fold) than
the levels seen in HT1080 cells. As discussed below, this ele-
vated level of activated MEK was associated with dramatic
effects on the in vitro and in vivo phenotypes of the stable
transfectants.
Cross talk between the pathways is bidirectional. Clear ev-
idence for cross talk (direct or indirect) was seen in both the
DN and activating mutant transfected clones. In the case of the
HT1080-Raf DN clones, there was no indication of negative-
feedback cross talk with the Rac-JNK pathway or RhoA (Fig.
1B, 2, and 1C, respectively). However, the MEK DN clones
showed decreased activity of JNK (Fig. 3A) but, again, not of
Rac and RhoA (Fig. 1B and C). The persisting levels of Rac-
GTP and RhoA-GTP can be explained by the fact that the
HT1080-MEK DN clones continue to express mutant N-ras,
thereby mediating continued activation of endogenous Rac
and RhoA. Thus, negative-feedback cross talk with JNK pre-
sumably originated from MEK or a downstream member and
occurred at the level of JNK directly or below Rac in the Rac
pathway. It is somewhat surprising that the Raf DN transfec-
tants did not show evidence of negative cross talk with JNK,
since the level of endogenous MEK activity decreased to a
level only slightly above that seen in the MEK DN transfec-
tants (compare Fig. 2A with Fig. 3A). In the case of the
MCH603c8 transfectants, both the Rafact and the MEKact
clones exhibited positive cross talk that involved both Rac and
RhoA and induced activation of JNK. It is, of course, possible
that subtle differences in the levels of activation of relevant
members of the respective pathways may have significant ef-
fects on the ability to cross talk, either positively or negatively.
Interestingly, the RhoAact mutants also showed activation of
Rac (Fig. 1B) whereas the HT1080-RhoA DN clones showed
no evidence of negative cross talk with the Rac (Fig. 1B) or
Raf-MEK-ERK pathway (data not shown). In the HT1080-
RhoA DN clones, Rac GTP and Raf-MEK-ERK activities
were observed to be at levels similar to that seen in HT1080
cells. This may reflect unidirectional cross talk or may be a
reflection of subtle differences in levels of activation or down-
regulation not revealed in these studies. It is well established
that twofold or even smaller increases or decreases in the level
of a signaling protein may have profound effects on the ulti-
mate target(s) (16). In our studies we find that activation of
Rac induces activation of RhoA and vice versa. This is consis-
tent with earlier observations (15). More recently, it has been
FIG. 8. Tumorigenicity assays of HT1080 (HT) and HT1080-DN transfec-
tants (A) and MCH603c8 (603) and MCH603c8-activating mutant transfectants
(B). Each point is the average of the tumor sizes of all sites inoculated (a total
of 6 for parental cells and 18 for the transfectants, combining three independent
clones). cumm, cubic millimeters.
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FIG. 9. Schematic diagrams of the downregulated and activated status of the downstream members of the Ras-mediated signaling pathways in the transfectants
compared to those of the parental HT1080 and MCH603c8 cells. The down and up arrows indicate downregulation and activation of kinase activity, respectively, of
those proteins that has occurred as a consequence of expression of transfected DN (HT1080-Raf DN, HT1080-MEK DN, and HT1080-Rac DN) and activated
(MCH603c8-Rafact, MCH603c8-MEKact, and MCH603c8-Racact) mutants, respectively. The horizontal and diagonal arrows indicate probable cross talk between the
Raf and Rac1 pathways. The positive or negative cross talk may be direct or indirect. Also, the specific level at which the cross talk takes place is not clear in every case.
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shown that Rac signaling antagonizes RhoA activity in mouse
NIH 3T3 cells (40). Our results are at variance with these
observations. As with many other Ras-related phenomena,
there may be multiple explanations, including differences in
cell lineages, Rac, and RhoA mutants studied and experimen-
tal conditions.
A limited degree of negative cross talk between Rac and the
Raf-dependent pathway was seen in the HT1080-Rac DN
clones. Raf activity was reduced to a level seen in MCH603c8
cells, but levels of activated MEK, ERK, and Elk-1 were un-
altered (Fig. 4A). There are several possible explanations for
the above finding: (i) there may be subtle threshold level effects
on activation; (ii) Ras may be able to activate MEK in a
Raf-independent fashion; and (iii) since we have not assessed
the activity of all the relevant Raf isoforms, there is a possi-
bility that continued activation of a Raf isoform other than
Raf-1 is responsible for the observed MEK–ERK–Elk-1 activ-
ity. In the MCH603c8-Racact clones, elevated levels of acti-
vated Raf, MEK, ERK, Elk-1, and RhoA were seen, indicating
active cross talk (Fig. 4B). In no case was Ras activity affected
(Fig. 1A), indicating that cross talk in either direction occurs
below this master signal transducer. The differences in potency
between the positive cross talk to the Raf-dependent pathway
in MCH603c8-Racact cells and negative cross talk from the
HT1080-Rac DN cells may again reflect the fact that subtle
differences in threshold levels of activation may influence
downstream signaling (16, 48). It must be noted, however, that
in the HT1080 cells the DN effects of each mutant are super-
imposed upon the constitutive signaling of the endogenous
mutant N-ras protein. The various levels of cross talking that
we have observed in these DN and constitutively active trans-
fectant cell lines are clearly complex. The mechanisms of cross
talk among the Ras signaling pathways, both positive and neg-
ative, remain obscure. Although the specificity of signaling and
interactions between partners involved in such signaling may
be facilitated by scaffold proteins (41), these possibilities re-
main untested. It is likely, however, that the transfectant cell
lines described in this report will prove to be useful experi-
mental models for future studies. The changes in levels of
activated protein, up or down, in all of the experiments were
not due to alterations in rates of transcription or translation of
the relevant proteins. No significant alterations were noted in
the total levels of each protein, which were assayed in each
experiment (data not shown).
Dissociation of in vitro-transformed phenotypic traits from
in vivo tumorigenic phenotypes. Several unexpected effects on
cytoskeletal architecture and in vitro growth characteristics
were seen in the various DN and constitutively active mutant
transfectants. We expected that the levels of activated Rac and
RhoA would have significant effects on the distribution of actin
microfilaments, based upon the observations of Hall and oth-
ers (2, 15). However, there was no effect on the well-organized
actin fibers in the MCH603c8-Racact clones (Fig. 5I). Although
there was a small degree of restoration of organized actin
stress fibers in the HT1080-Rac DN clones, it did not come
close to the extensive stress fiber organization seen in
MCH603c8 cells (Fig. 8B and E). The most dramatic effects
were seen in the MEK transfectants. The HT1080-MEK DN
clones acquired distinct organized actin microfilament cy-
toskeletons (Fig. 5D). Conversely, the MCH603c8-MEKact
clones had a completely disorganized pattern of actin staining
(Fig. 5H). The lack of an effect of activated or DN Rac and
RhoA transfectants on the organization of actin stress fibers
was unexpected. However, it should be noted that most studies
of RhoA and Rac-Cdc42 effects on stress fiber induction are
short term, including microinjection of relevant proteins (2, 15,
34). Chronic stimulation, as seen in Ras transformation assays
and in cancer cells with endogenous mutant Ras alleles, is most
often accompanied by inhibition of stress fiber formation (2).
The effects are also likely to be cell type specific. The signaling
circuitry associated with N-ras-mediated control of stress fiber
formation (or lack of it) in HT1080 cells is clearly complex.
However, MEK or its downstream partner(s) appears to be a
critical component of that circuitry. It is interesting in this
context to note that earlier we had observed that treatment of
HT1080 cells with the MEK inhibitor PD098059 resulted in the
restoration of organized actin stress fibers (32). More recently,
we have transfected MCH603c8-MEKact cells (disorganized
actin stress fibers) with MKP-1, the phosphatase that dephos-
phorylates and inactivates ERK1 and -2 (46). We found that
levels of active ERK decrease to the levels observed in
MCH603c8, accompanied by a dramatic restoration of actin
stress fibers (S. Gupta et al., unpublished data). The levels of
constitutively active MEK remain high in these double trans-
fectants. Thus, a critical component of the regulation of actin
stress fiber formation in these cells is the activated status of
ERK. Furthermore, the MCH603c8–MEKact–MKP21 double
transfectants retained their aggressive tumorigenic phenotype.
Thus, as with the MEK DN transfectants, the restoration of
organized actin stress fibers had no effect on the aggressive
tumorigenic phenotype.
The kinetics of in vitro growth also had no influence on the
aggressive nature of the tumorigenic phenotype. The HT1080
Raf and MEK DN clones had in vitro growth rates intermedi-
ate between those of HT1080 and MCH603c8 (Fig. 6). How-
ever, all of them retained the aggressive in vivo tumorigenic
phenotype (Fig. 8). All of the MCH603c8 activating mutant
clones retained the same in vitro growth kinetics as the paren-
tal MCH603c8 cells (Fig. 6). However, the MCH603c8-MEKact
clones acquired a highly aggressive tumorigenic phenotype
(Fig. 8). Thus, in vitro growth kinetics were dissociable from in
vivo tumor growth kinetics.
The one in vitro trait that did show some correlation with in
vivo tumor kinetics was anchorage-independent growth (Fig.
7). The only MCH603c8 transfectant cells to form colonies in
soft agar were the MEKact clones. However, colonies formed
only when cells were plated at high density and not at low
density (104/dish). Interestingly, the same phenomenon was
seen with the HT1080-MEK DN clones. Thus, partial restora-
tion of the ability of MCH603c8-MEKact clones to grow in soft
agar was associated with the conversion to an aggressive tu-
morigenic phenotype. However, the partial loss of anchorage
independence in the HT1080-MEK DN clones had no effect
on the kinetics of tumor growth. Although it is possible that
autocrine effects influence growth in soft agar or actin stress
fiber formation, we found no evidence for this in conditioned-
medium experiments (data not shown).
A summary of the in vitro and in vivo phenotypic traits of the
parental cells and their stable transfectants is presented in
Table 2. Although the dissociation of in vitro traits of trans-
formation from the ability to form tumors may seem surprising
at first glance, given the preponderance of reports identifying
such correlations, many exceptions have also been reported
(44, 45). It is likely that such correlations are dependent on cell
type, host species, and the nature of the genetic mutations that
have occurred in the genesis of any given cancer.
No single Ras signaling pathway is associated with the ag-
gressive tumorigenic phenotype. The only manipulation of
HT1080 or MCH603c8 cells that produced a change in the
respective tumorigenic phenotype was the overexpression of
activated MEK in MCH603c8-MEKact transfectants. This re-
sulted in the acquisition of an aggressive tumorigenic pheno-
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type that was even more aggressive than that of HT1080 cells
(Fig. 8). Activation of MEK has been shown to be both nec-
essary and sufficient for neoplastic transformation of mouse
NIH 3T3 cells (11). However, a careful perusal of the results in
our study show that activation of MEK and its downstream
partners alone cannot explain our result. In the case of the
HT1080 transfectants, both Raf DN and MEK DN clones show
evidence of decreased activity of MEK and downstream mem-
bers and, in the case of MEK DN clones, decreased activity of
JNK. However, there is no effect on the aggressive tumorigenic
phenotype. It should be noted that, with the exception of
activated Ras and Rac, the Raf DN clones have the same
biochemical profile of activated members of the pathways as
MCH603c8.
A summary of the activated status of each member of the
Ras-mediated signaling pathways in these transfectants com-
pared to the parental MCH603c8 cells, and the HT1080 (mu-
tant N-ras) cells, is presented in Fig. 9. The Rafact, MEKact,
and Racact transfectants of MCH603c8 are particularly infor-
mative regarding the role of activated MEK in conversion to an
aggressive tumorigenic phenotype. Both the Rafact and Racact
clones had levels of activated Raf, MEK, ERK, and Elk-1
approximately equal to that seen in HT1080 cells (Fig. 3 and
4). Thus, the Rafact and Racact clones show essentially the
same profiles of activated members of the signaling pathways
as HT1080, with the exception that Ras is not activated. How-
ever, neither the MCH603c8-Rafact nor the Racact clones ac-
quired the aggressive tumorigenic phenotype. The MCH603c8-
MEKact transfectants had levels of activated MEK that were
approximately 10-fold higher than those seen in MCH603c8
cells and 3-fold higher than those in HT1080 cells (Fig. 3B). All
of these transfectants acquired the aggressive tumorigenic phe-
notype. The MCH603c8-MEKact transfectants also had levels
of activated ERK and Elk-1 above that seen in HT1080 cells.
In related studies (Gupta et al., unpublished), we have created
MCH603c8-MEKact–MKP-1 double transfectants in which the
high levels of activated MEK are retained but levels of acti-
vated ERK drop to those seen in the parental MCH603c8 cells.
These double transfectants retain their aggressive tumorigenic
phenotype. Thus, the elevated levels of activated MEK do,
indeed, seem to be a critical factor for aggressive tumorigenic
growth.
Evidence for a novel Ras-dependent pathway. Taken to-
gether, these data do not support the contention that activation
of MEK alone is the critical event for acquisition of the ag-
gressive tumorigenic phenotype. Neither do the data support
the notion that activation of downstream members and cross
activation of the Rac and RhoA pathways are sufficient or
necessary (see the data for the HT1080 DN mutants) for the
aggressive tumorigenic phenotype. These results lead us to
conclude that overexpression of activated MEK in MCH603c8-
MEKact transfectants is the key event in converting these cells
to an aggressive tumorigenic phenotype. We further speculate
that this overexpression of activated MEK results in a “spill-
over” effect that activates an as-yet-unidentified pathway that is
critical for this conversion. An interesting possibility is that
overexpression of activated MEK may perturb the protein scaf-
folding that contributes to the specificity of MAPK signaling
(41, 48) and allow “forbidden” partners to interact and become
activated. We speculate that this pathway may also be activated
by mutant Ras in a MEK-independent manner. We base this
conclusion on the fact that HT1080-MEK DN transfectants
have significantly lower levels of endogenous activated MEK
but retain their activated-Ras levels (Fig. 1A) and their aggres-
sive tumorigenic phenotype.
It is possible that the key Ras-dependent pathway may be an
already-identified one not examined in this study. It may be
equally possible that a hitherto-undiscovered pathway is in-
volved. We are actively pursuing these possible scenarios. We
do know that activation of the PI3K pathway is not the critical
event (Gupta et al., unpublished data). PI3K is constitutively
active in both HT1080 and MCH603c8 cells due to constitutive
PDGF production and consequent activation of the cognate
PDGF receptor.
Therapeutic possibilities. Modulation of activated Ras ac-
tivity and/or its downstream effectors is being actively pursued
by pharmacologic intervention strategies (29). These include
Ras and MEK inhibitors. Our studies with a human fibrosar-
coma cell line possessing a mutant N-ras allele predict that Ras
inhibitors have a potential benefit but that MEK inhibitors do
not. If a critical novel pathway is involved in the control of the
aggressive tumorigenic phenotype, it will provide an additional
therapeutic target for treatment of cancers expressing onco-
genic Ras mutant proteins. It remains to be seen if such a
putative novel pathway is common to N-, H-, and K-ras sig-
naling.
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